Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

WALTHAM, Mass., Sept. 30, 2022 -- Apellis Pharmaceuticals, Inc. , a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3... | September 30, 2022

Related Keywords

Waltham ,Illinois ,United States ,The Academy ,Chicago ,American ,Intravitreal Pegcetacoplan ,Federico Grossi ,Meredith Kaya ,Lissa Pavluk ,Analysis Of The Academy ,Linkedin ,Exchange Commission On ,Twitter ,Drug Administration ,American Academy Of Ophthalmology ,Nasdaq ,Exchange Commission ,Research Group ,Apellis Pharmaceuticals Inc ,European Medicines Agency ,Lancet Glob Health ,American Academy ,Annual Meeting ,Priority Review ,Prescription Drug User Fee Act ,Geographic Atrophy Secondary ,Two Year Outcomes ,Randomized Phase ,Geographic Atrophy ,Month Results ,Fast Track ,Private Securities Litigation Reform Act ,Apelli Annual Report ,Apellis Pharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,022 ,Apellis ,Lobal ,Iopharmaceutical ,Company ,End ,Leader ,N ,Oday ,Nnounced ,Hat ,Four ,Mural ,Presentations ,F ,Data ,Rom ,The ,Hase Apls Us03753u1060 ,